Axonics (NASDAQ:AXNX) Announces Earnings Results

Axonics (NASDAQ:AXNX) released its earnings results on Thursday. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.03, Briefing.com reports. Axonics had a negative return on equity of 2.58% and a negative net margin of 4.12%. The firm had revenue of $114.57 million for the quarter, compared to analyst estimates of $112.83 million. During the same quarter in the prior year, the firm posted ($0.15) earnings per share. The company’s quarterly revenue was up 23.3% on a year-over-year basis.

Axonics Trading Up 0.1 %

NASDAQ:AXNX traded up $0.07 during trading hours on Friday, hitting $68.51. The stock had a trading volume of 428,331 shares, compared to its average volume of 846,401. Axonics has a 1-year low of $48.30 and a 1-year high of $69.68. The business has a 50 day simple moving average of $67.54 and a two-hundred day simple moving average of $67.73. The company has a market cap of $3.50 billion, a PE ratio of -214.22 and a beta of 0.83.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reiterated a “hold” rating on shares of Axonics in a research note on Monday, May 6th. Eight research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $69.57.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.